Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

Leukemia Research

Volumn 40, Issue , 2015, Pages 1-9

  Vidriales, María Belén ^a,b   Pérez López, Estefanía ^a   Pegenaute, Carlota ^a   Castellanos, Marta ^a   Pérez, José Juan ^a   Chandía, Mauricio ^a   Díaz Mediavilla, Joaquín ^c   Rayón, Consuelo ^d   de las Heras, Natalia ^e   Fernández Abellán, Pascual ^f   Cabezudo, Miguel ^g   de Coca, Alfonso García ^h   Alonso, Jose Ma ⁱ   Olivier, Carmen ^j   Hernández Rivas, Jesús Ma ^a,b   Montesinos, Pau ^k   Fernández, Rosa ^l   García Suárez, Julio ^m   García, Magdalena ⁿ   Sayas, María José ^o   Paiva, Bruno ^a,b   González, Marcos ^a,b   Orfao, Alberto ^b,p   San Miguel, Jesús F ^a,b   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b CSIC   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL DE LEÓN   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g Hospital Provincial   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

ⁱ HOSPITAL RÍO CARRIÓN   (Spain)

^j Hospital Complejo Asistencial de Segovia   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^m HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

ⁿ HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^o HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^p UNIVERSITY OF SALAMANCA   (Spain)

more..

Author keywords

Acute myeloid leukaemia; Flow cytometry; Minimal residual disease; Prognosis

Indexed keywords

BIOLOGICAL MARKER; BUSULFAN; CYTARABINE; ETOPOSIDE; IDARUBICIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER PROGNOSIS; CANCER REGRESSION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INTERMEDIATE RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; VALIDATION STUDY; AGED; CHROMOSOME ABERRATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATHOLOGY;

AGED; CHROMOSOME ABERRATIONS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM, RESIDUAL;

EID: 84948807798     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.10.002     Document Type: Article

References (45)

1. Vidriales M.B., Perez J.J., Lopez-Berges M.C., Gutierrez N., Ciudad J., Lucio P., et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003, 101(12):4695-4700.
2. Borowitz M.J., Devidas M., Hunger S.P., Bowman W.P., Carroll A.J., Carroll W.L., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111(12):5477-5485.
3. Basso G., Veltroni M., Valsecchi M.G., Dworzak M.N., Ratei R., Silvestri D., et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J. Clin. Oncol. 2009, 27(31):5168-5174.
4. Leung W., Pui C.H., Coustan-Smith E., Yang J., Pei D., Gan K., et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012, 120(2):468-472.
5. J.M. Ribera, A. Oriol, M. Morgades, P. Montesinos, J. Sarra, J. Gonzalez-Campos, et al., Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. (1527-7755 (Electronic)).
6. San Miguel J.F., Martinez A., Macedo A., Vidriales M.B., Lopez-Berges C., Gonzalez M., et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997, 90(6):2465-2470.
7. San Miguel J.F., Vidriales M.B., Lopez-Berges C., Diaz-Mediavilla J., Gutierrez N., Canizo C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98(6):1746-1751.
8. Venditti A., Buccisano F., Del Poeta G., Maurillo L., Tamburini A., Cox C., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000, 96(12):3948-3952.
9. Coustan-Smith E., Ribeiro R.C., Rubnitz J.E., Razzouk B.I., Pui C.H., Pounds S., et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br. J. Haematol. 2003, 123(2):243-252.
10. Buccisano F., Maurillo L., Spagnoli A., Del Principe M.I., Fraboni D., Panetta P., et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010, 116(13):2295-2303.
11. Kern W., Voskova D., Schoch C., Hiddemann W., Schnittger S., Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004, 104(10):3078-3085.
12. Voskova D., Schnittger S., Schoch C., Haferlach T., Kern W. Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma 2007, 48(1):80-88.
13. Al-Mawali A., Gillis D., Hissaria P., Lewis I. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am. J. Clin. Pathol. 2008, 129(6):934-945.
14. Olaru D., Campos L., Flandrin P., Nadal N., Duval A., Chautard S., et al. Multiparametric analysis of normal and postchemotherapy bone marrow: implication for the detection of leukemia-associated immunophenotypes. Cytom. B Clin. Cytom. 2008, 74(1):17-24.
15. Walter R.B., Buckley S.A., Pagel J.M., Wood B.L., Storer B.E., Sandmaier B.M., et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013, 122(10):1813-1821.
16. Coustan-Smith E., Song G., Clark C., Key L., Liu P., Mehrpooya M., et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011, 117(23):6267-6276.
17. Macedo A., San Miguel J.F., Vidriales M.B., Lopez-Berges M.C., Garcia-Marcos M.A., Gonzalez M., et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J. Clin. Pathol. 1996, 49(1):15-18.
18. Baer M.R., Stewart C.C., Dodge R.K., Leget G., Sule N., Mrozek K., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001, 97(11):3574-3580.
19. Voskova D., Schoch C., Schnittger S., Hiddemann W., Haferlach T., Kern W. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytom. B Clin. Cytom. 2004, 62(1):25-38.
20. Kern W., Haferlach T., Schoch C., Loffler H., Gassmann W., Heinecke A., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood 2003, 101(1):64-70.
21. Kohnke T., Sauter D., Ringel K., Hoster E., Laubender R.P., Hubmann M., et al. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 2015, 2:377-386.
22. Sievers E.L., Lange B.J., Alonzo T.A., Gerbing R.B., Bernstein I.D., Smith F.O., et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003, 101(9):3398-3406.
23. Feller N., van der Pol M.A., van Stijn A., Weijers G.W., Westra A.H., Evertse B.W., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004, 18(8):1380-1390.
24. Langebrake C., Creutzig U., Dworzak M., Hrusak O., Mejstrikova E., Griesinger F., et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J. Clin. Oncol. 2006, 24(22):3686-3692.
25. Laane E., Derolf A.R., Bjorklund E., Mazur J., Everaus H., Soderhall S., et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006, 91(6):833-836.
26. Maurillo L., Buccisano F., Del Principe M.I., Del Poeta G., Spagnoli A., Panetta P., et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J. Clin. Oncol. 2008, 26(30):4944-4951.
27. Rubnitz J.E., Inaba H., Dahl G., Ribeiro R.C., Bowman W.P., Taub J., et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010, 11(6):543-552.
28. Walter R.B., Gooley T.A., Wood B.L., Milano F., Fang M., Sorror M.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J. Clin. Oncol. 2011, 29(9):1190-1197.
29. Loken M.R., Alonzo T.A., Pardo L., Gerbing R.B., Raimondi S.C., Hirsch B.A., et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012, 120(8):1581-1588.
30. S.D. Freeman, P. Virgo, S. Couzens, D. Grimwade, N. Russell, R.K. Hills, A.K. Burnett, Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia, (2013) (1527-7755 (Electronic)).
31. Terwijn M., van Putten W.L., Kelder A., van der Velden V.H., Brooimans R.A., Pabst T., et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J. Clin. Oncol. 2013, 31(31):3889-3897.
32. Walter R.B., Gyurkocza B., Storer B.E., Godwin C.D., Pagel J.M., Buckley S.A., et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 2015, 29(1):137-144.
33. Anthias C., Dignan F.L., Morilla R., Morilla A., Ethell M.E., Potter M.N., et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transpl. 2014, 49(5):679-683.
34. Macedo A., Orfao A., Ciudad J., Gonzalez M., Vidriales B., Lopez-Berges M.C., et al. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995, 9(11):1896-1901.
35. Inaba H., Coustan-Smith E., Cao X., Pounds S.B., Shurtleff S.A., Wang K.Y., et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J. Clin. Oncol. 2012, 30(29):3625-3632.
36. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 1990, 8(5):813-819.
37. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92(7):2322-2333.
38. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100(13):4325-4336.
39. Bacher U., Haferlach T., Alpermann T., Kern W., Schnittger S., Haferlach C. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype. Leukemia 2013, 27(2):496-500.
40. Kohnke T., Sauter D., Ringel K., Hoster E., Laubender R.P., Hubmann M., et al. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 2015, 29(2):377-386.
41. van der Velden V.H., van der Sluijs-Geling A., Gibson B.E., te Marvelde J.G., Hoogeveen P.G., Hop W.C., et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010, 24(9):1599-1606.
42. Kalina T., Flores-Montero J., van der Velden V.H., Martin-Ayuso M., Bottcher S., Ritgen M., et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012, 26(9):1986-2010.
43. van Dongen J.J., Lhermitte L., Bottcher S., Almeida J., van der Velden V.H., Flores-Montero J., et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012, 26(9):1908-1975.
44. Pedreira C.E., Costa E.S., Almeida J., Fernandez C., Quijano S., Flores J., et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A 2008, 73A(12):1141-1150.
45. Fiser K., Sieger T., Schumich A., Wood B., Irving J., Mejstrikova E., et al. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. Cytometry A 2012, 81(1):25-34.